Market Place
Sourcing Support
Cyclo Therapeutics Reports Q3 2024 Results & Update
14 Nov 2024 //
BUSINESSWIRE
Cyclo Therapeutics Presents Phase 3 Safety Data for Niemann-Pick Disease C1
05 Sep 2024 //
BUSINESSWIRE
Rafael Holdings and Cyclo Therapeutics Enter Into a Definitive Merger Agreement
22 Aug 2024 //
BUSINESSWIRE
Cyclo Therapeutics Reports Q2 2024 Financial Results And Update
15 Aug 2024 //
BUSINESSWIRE
Cyclo Therapeutics Gets European Patent For Alzheimer`s Treatment
29 Jul 2024 //
BUSINESSWIRE
Cyclo Therapeutics to Present at SSIEM Annual Symposium 2024
25 Jun 2024 //
BUSINESSWIRE
Cyclo Therapeutics Completes Enrolment TransportNPC Pivotal NPC1 Trial
30 May 2024 //
BUSINESSWIRE
Cyclo Therapeutics Reports Q1 2024 Financials, Business Update
16 May 2024 //
BUSINESSWIRE
Cyclo Reports Full Year 2023 Financial Results and Provides Business Update
18 Mar 2024 //
BUSINESSWIRE
Cyclo Announces Issuance of U.S. Patent Covering the Use of Trappsol® Cyclo
14 Mar 2024 //
BUSINESSWIRE
Cyclo Announces Allowance of Patent Application for Alzheimer’s Disease
29 Jan 2024 //
BUSINESSWIRE
Cyclo Therapeutics, Inc. Completes Merger with Applied Molecular Transport Inc.
27 Dec 2023 //
BUSINESSWIRE
Cyclo Announces Outcome from Meeting with FDA Discussing Trappsol Cyclo Program
18 Dec 2023 //
BUSINESSWIRE
Cyclo Therapeutics to Present at the 20th Annual WORLDSymposium™ 2024
21 Nov 2023 //
BUSINESSWIRE
Cyclo Therapeutics Reports Third Quarter 2023 Financial Results
15 Nov 2023 //
BUSINESSWIRE
Cyclo Therapeutics Announces Early Exercise of Warrants by Board Members
23 Oct 2023 //
BUSINESSWIRE
Cyclo Therapeutics to Present at 8th Annual Dawson James Conference
05 Oct 2023 //
BUSINESSWIRE
Cyclo and Applied Molecular Transport Enter into a Definitive Merger Agreement
21 Sep 2023 //
BUSINESSWIRE
Cyclo Therapeutics Reports Second Quarter 2023 Financial Results
15 Aug 2023 //
BUSINESSWIRE
Cyclo Announces Closing of $5.0M Private Placement with Rafael Holdings, Inc.
02 Aug 2023 //
BUSINESSWIRE
Cyclo Announces Publication of+ve Data from Ph2 Clinical Study of Trappsol Cyclo
29 Jun 2023 //
BUSINESSWIRE
Cyclo Announces Allowance of Patent from EU Patent Office for Trappsol® Cyclo
12 Jun 2023 //
PRESS RELEASE
Cyclo Announces Execution of Definitive Agreement with Rafael Holdings
05 Jun 2023 //
BUSINESSWIRE
Cyclo Therapeutics Provides Business Update and Reports 1Q 2023 FYR Results
15 May 2023 //
BUSINESSWIRE
Cyclo Therapeutics announces update on Trappsol Cyclo clinical programme
13 Jan 2023 //
PHARMABIZ
Cyclo Provides Clinical Program Update and Highlights Recent Achievements
11 Jan 2023 //
BUSINESSWIRE
Cyclo Therapeutics to Present at Virtual Investor 2023 Companies to Watch Event
10 Jan 2023 //
BUSINESSWIRE
Cyclo Therapeutics begins subject dosing in trial of early AD therapy
10 Jan 2023 //
CLINICALTRIALSARENA
Cyclo Therapeutics Announces First Patient Dosed in Phase 2b Study of Trappsol
09 Jan 2023 //
BUSINESSWIRE
Cyclo Therapeutics Announces Abstract Accepted for Poster Presentation at SIMD
04 Jan 2023 //
BUSINESSWIRE
Cyclo Therapeutics Announces Closing of $4.2 Million Registered Direct Offering
04 Jan 2023 //
BUSINESSWIRE
Cyclo Therapeutics Announces $4.2 Million Registered Direct Offering
30 Dec 2022 //
BUSINESSWIRE
Cyclo Therapeutics Announces Publication of Phase 1 Data for Trappsol Cyclo
18 Oct 2022 //
BUSINESSWIRE
Cyclo Commences Phase 2b Study of Trappsol Cyclo
04 Oct 2022 //
BUSINESSWIRE
Cyclo Therapeutics Provides Business Update
28 Sep 2022 //
BUSINESSWIRE
Cyclo to Present at the H.C. Wainwright 24th Annual Global Investment Conference
07 Sep 2022 //
BUSINESSWIRE
Cyclo Therapeutics to Present at the NNPDF-INPDA Conferences 2022
21 Jul 2022 //
BUSINESSWIRE
Cyclo Therapeutics to Present at the World Orphan Drug Congress USA 2022
11 Jul 2022 //
BUSINESSWIRE
Cyclo Tx to Present at the 2022 NPC Patient and Family Conference
21 Jun 2022 //
BUSINESSWIRE
Cyclo Therapeutics to Participate in the H.C. Wainwright Conference
18 May 2022 //
BUSINESSWIRE
Cyclo Therapeutics Reports First Quarter 2022 Financial Results
12 May 2022 //
BUSINESSWIRE
Cyclo Therapeutics to Participate in the Virtual Investor AD Spotlight Event
29 Mar 2022 //
BUSINESSWIRE
Cyclo Tx Collaborates with Wits Commercial to Explore Use of Trappsol Cyclo
24 Mar 2022 //
BUSINESSWIRE
Cyclo Tx to Participate in 2022 Virtual Growth Conference by Maxim Group
23 Mar 2022 //
BUSINESSWIRE
Cyclo Tx Provides Business Update and Reports Full Year 2021 Financial Results
14 Mar 2022 //
BUSINESSWIRE
Cyclo Tx to Present at the Oppenheimer 32nd Annual Healthcare Conference
10 Mar 2022 //
BUSINESSWIRE
Cyclo Tx to Present Overview of Pivotal Phase 3 Study for Trappsol Cyclo
08 Feb 2022 //
BUSINESSWIRE
Cyclo Therapeutics Announces Formation of Global Steering Committee
03 Feb 2022 //
BUSINESSWIRE
Cyclo Therapeutics Appoints Caroline Hastings as Global Principal Investigator
09 Dec 2021 //
BUSINESSWIRE
Cyclo Announces Pricing of $11.7M Underwritten Public Offering of Common Stock
16 Nov 2021 //
BUSINESSWIRE
Cyclo Therapeutics Provides Business Update & Reports Q3 2021 Financial Results
15 Nov 2021 //
BUSINESSWIRE
Cyclo Therapeutics to Present at H.C. Wainwright 23rd Investment Conference
08 Sep 2021 //
BUSINESSWIRE
Cyclo Therapeutics reports second quarter 2021 financial results.
17 Aug 2021 //
BUSINESSWIRE
Cyclo Reports +Ve Safety and Efficacy Data from Study of Trappsol® Cyclo™
30 Jul 2021 //
BUSINESS WIRE
Cyclo Therapeutics Commences Manufacturing for Trappsol® Cyclo™
27 Jul 2021 //
PR NEWSWIRE
Cyclo to Present at the 2021 NPC Patient
21 Jun 2021 //
BUSINESSWIRE
Cyclo Therapeutics starts enrolment in Phase III NPC1 treatment trial
18 Jun 2021 //
CLINICAL TRAILS ARENA
Cyclo Therapeutics Commences Patient Enrollment in TransportNPC
17 Jun 2021 //
BUSINESSWIRE
Cyclo Therapeutics Commences Patient Enrollment in TransportNPC
16 Jun 2021 //
BUSINESSWIRE
Cyclo Therapeutics Announces Launch of New Website
15 Jun 2021 //
BUSINESSWIRE
